Vyome Holdings (NASDAQ: RSLS) files Vyome Q2 data and pro formas

Rhea-AI Filing Summary

Vyome Holdings, Inc. reported that it has completed its previously announced merger in which Raider Lifesciences Inc., a subsidiary of the company, merged into Vyome Therapeutics, Inc., with Vyome surviving as a subsidiary. Following the merger, the registrant was renamed Vyome Holdings, Inc. and Vyome continues as Vyome Therapeutics, Inc.

The company is providing Vyome’s financial statements for the quarter ended June 30, 2025, Vyome’s Management’s Discussion and Analysis for that quarter, and unaudited pro forma condensed combined financial statements as exhibits. This information is being made available so it can be incorporated by reference into Vyome Holdings’ shelf registration statement on Form S-3.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 2, 2025

VYOME HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		1-37897		26-1828101
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Harvard Square, One Mifflin Place, Suite 400 Cambridge, MA		02138
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (973) 832-8147

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		HIND		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

As previously disclosed, on August 15, 2025, Vyome Holdings, Inc. (f/k/a ReShape Lifesciences Inc.) (the “Company”) completed the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the “Merger Agreement”), by and among the Company, Raider Lifesciences Inc., a wholly owned subsidiary of the Company (“Merger Sub”), and Vyome Therapeutics, Inc. (“Vyome”). Pursuant to the Merger Agreement, Merger Sub merged with and into Vyome, with Vyome surviving the merger as a subsidiary of the Company (the “Merger”). As a result of the Merger, the Company was renamed “Vyome Holdings, Inc.” and Vyome continued under its name as Vyome Therapeutics, Inc., in each case effective before the open of trading on August 15, 2025.

This Current Report on Form 8-K is being filed to provide (1) Vyome’s financial statements for the quarter ended June 30, 2025, filed as Exhibit 99.1 hereto; (2) Vyome’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the quarter ended June 30, 2025, filed as Exhibit 99.2 hereto; and (3) unaudited pro forma condensed combined financial statements giving effect to the Merger, filed as Exhibit 99.3 hereto; so that such information is incorporated by reference into the Company’s shelf registration statement on Form S-3 (File No. 333-287168) filed with the Securities and Exchange Commission on May 9, 2025 under the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Financial Statements of Vyome for the quarter ended June 30, 2025
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations of Vyome for the quarter ended June 30, 2025
99.3		Unaudited Pro Forma Condensed Combined Financial Statements
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VYOME HOLDINGS, INC.
September 2, 2025	By:	/s/ Venkat Nelabhotla
	Name:	Venkat Nelabhotla
	Title:	President & Chief Executive Officer

2

FAQ

What did Vyome Holdings (RSLS) disclose in this Form 8-K?

Vyome Holdings, Inc. disclosed that it has completed the previously announced merger involving Vyome Therapeutics, Inc. and is providing Vyome’s standalone and pro forma combined financial information as exhibits.

Which merger is described in the Vyome Holdings 8-K?

The report describes the merger under the Agreement and Plan of Merger dated July 8, 2024, under which Raider Lifesciences Inc., a Vyome Holdings subsidiary, merged with and into Vyome Therapeutics, Inc., with Vyome surviving as a subsidiary.

What financial statements are included as exhibits in the Vyome Holdings 8-K?

The exhibits include Vyome’s financial statements for the quarter ended June 30, 2025 (Exhibit 99.1), Vyome’s Management’s Discussion and Analysis for that quarter (Exhibit 99.2), and unaudited pro forma condensed combined financial statements (Exhibit 99.3).

Why is Vyome providing Vyome Therapeutics’ Q2 2025 financial information?

The company is providing Vyome Therapeutics’ quarter ended June 30, 2025 financial statements, MD&A, and unaudited pro forma condensed combined financial statements so this information can be incorporated by reference into its Form S-3 shelf registration statement.

Did the merger change the company’s name?

Yes. As a result of the merger, the registrant was renamed Vyome Holdings, Inc., while the acquired entity continues under the name Vyome Therapeutics, Inc.

On which market is Vyome Holdings’ common stock listed and under what symbol?

Vyome Holdings’ common stock, with a par value of $0.001 per share, is listed on The Nasdaq Capital Market under the trading symbol HIND.